Mercury Laboratories Ltd
₹760
(0%)
Mon, 19 Oct 2026, 01:07 am
Health Technology
Pharmaceuticals: Major
24.5KMercury Laboratories Ratios
| Particulars | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 1.43 | 13.28 | 17.75 | 23.24 | 14.34 | 10.45 | 14.45 | 16.34 | 12.59 | 17.66 | 31.25 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0.26 | 2.38 | 1.96 | 1.78 | 1.40 | 1.05 | 2.09 | 1.44 | 1.54 | 1.96 | 1.83 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0.11 | 1.10 | 1 | 0.90 | 0.73 | 0.59 | 1.12 | 1 | 0.93 | 1.32 | 1.31 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 1.36 | 0 | 46.59 | 11.53 | 9.84 | 7.21 | 10.18 | 12.27 | 32.85 | 12.69 | 27.14 |
| Enterprise value | 0 | 0 | 0 | 0 | 12.43Cr | 58.21Cr | 54Cr | 52.77Cr | 48.76Cr | 38.4Cr | 79.34Cr | 57.25Cr | 68.77Cr | 97.18Cr | 102Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 2.10 | 8.81 | 7.62 | 11.62 | 8.34 | 6.08 | 7.76 | 7.83 | 7.86 | 10.60 | 14.21 |
| Debt to equity ratio | 0.34 | 0.32 | 0.70 | 0.73 | 0.49 | 0.34 | 0.30 | 0.37 | 0.33 | 0.22 | 0.19 | 0.15 | 0.13 | 0.11 | 0.10 |
| Return on equity % | 0 | 25.59 | 22.62 | 23.18 | 19.75 | 19.62 | 11.67 | 7.91 | 10.26 | 10.59 | 15.50 | 9.23 | 12.98 | 11.72 | 6.02 |
Mercury Laboratories Ltd Ratios
The Mercury Laboratories Ltd Ratios page provides a complete fundamental analysis of Mercury Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Mercury Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Mercury Laboratories Ltd (NSE: , BSE: 538964) is currently trading at ₹760, with a market capitalization of ₹91.2Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Mercury Laboratories Ltd remains a key stock for fundamental analysis using Mercury Laboratories Ltd Ratios.
Mercury Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Mercury Laboratories Ltd P/E ratio currently stands at 31.25, making it one of the most tracked metrics in Mercury Laboratories Ltd Ratios.
Historically, the Mercury Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2024: 31.25
- 2023: 17.66
- 2022: 12.59
- 2021: 16.34
- 2020: 14.45
The rising Mercury Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Mercury Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.83.
Historical P/B trend:
- 2024: 1.83
- 2023: 1.96
- 2022: 1.54
- 2021: 1.44
Mercury Laboratories Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Mercury Laboratories Ltd P/S ratio currently stands at 1.31, an important part of Mercury Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 1.31
- 2023: 1.32
- 2022: 0.93
- 2021: 1
A stable or declining Mercury Laboratories Ltd P/S ratio indicates cautious market sentiment.
Mercury Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Mercury Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 27.14.
Historical Mercury Laboratories Ltd Price to Cash Flow Ratio:
- 2024: 27.14
- 2023: 12.69
- 2022: 32.85
- 2021: 12.27
- 2020: 10.18
The rising Mercury Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Mercury Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Mercury Laboratories Ltd EV currently stands at ₹102Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 102Cr
- 2023: 97.18Cr
- 2022: 68.77Cr
- 2021: 57.25Cr
Mercury Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Mercury Laboratories Ltd EV/EBITDA ratio is currently 14.21, a key metric in Mercury Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 14.21
- 2023: 10.60
- 2022: 7.86
- 2021: 7.83
Higher Mercury Laboratories Ltd EV/EBITDA suggests premium valuation.
Mercury Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Mercury Laboratories Ltd D/E ratio is currently 0.10, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.10
- 2023: 0.11
- 2022: 0.13
- 2021: 0.15
Mercury Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Mercury Laboratories Ltd ROE currently stands at 6.02%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 6.02
- 2023: 11.72
- 2022: 12.98
- 2021: 9.23
Declining ROE indicates pressure on profitability.
Mercury Laboratories Ltd Ratios Analysis Summary
The Mercury Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Mercury Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Mercury Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
